1. Home
  2. Companies
  3. NX1
  4. Announcements

Nexalis Therapeutics (ASX:NX1)

ASX announcement history & article coverage

19
Total announcements
(in last 3 months)
5
With article
14
No article
Article coverage
26%
Transparent by design. Announcments by Nexalis Therapeutics (ASX:NX1) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.

6 July 2026 · 11:48 am AEST ⚡ Price SensitiveMaterialUnexpected ASX Filing
Update on Funding Facility and Clinical Program
Nexalis Therapeutics halts Point8 funding talks, completes IRX-616a Phase 1 trial with positive results, reassesses clinical plans
Periodic Reports - OtherProgress Report
65
Nexalis Therapeutics Halts Point8 Funding Talks, Completes IRX-616a Phase 1 Trial with Positive Results Healthcare Wrap - Week 28 (6 July -> 10 July) 2026 Wrap

25 June 2026 · 03:52 pm AEST ASX Filing
Director Appointment/Resignation
Initial Director's Interest NoticeFinal Director's Interest Notice

29 May 2026 · 06:23 pm AEST ASX Filing
2026 AGM results
Results of Meeting
29 May 2026 · 04:14 pm AEST ASX Filing
2026 AGM slides
Company PresentationChair's Address to Shareholders
28 May 2026 · 09:48 am AEST ⚡ Price SensitiveMaterial ASX Filing
Reinstatement to Official Quotation
Nexalis Therapeutics Ltd reinstated to trading following debt facility announcement
Reinstatement to Official Quotation
50
Nexalis Secures $53M Funding to Replace Debt and Push Clinical Trials
28 May 2026 · 09:48 am AEST ⚡ Price SensitiveMaterialUnexpected ASX Filing
Binding Letter of Intent to replace existing $53m facility
Nexalis secures $53M funding facility with Point8 Capital to replace LFO debt and advance clinical trials
Issued Capital - OtherProgress Report
75
Nexalis Secures $53M Funding to Replace Debt and Push Clinical Trials Healthcare Wrap - Week 22 (25 May -> 29 May) 2026 Wrap
26 May 2026 · 10:34 am AEST ⚡ Price SensitiveMaterial ASX Filing
Suspension from Quotation
Nexalis Therapeutics Requests Voluntary Suspension Pending Debt Facility Announcement
Suspension from Official Quotation
50
Nexalis Therapeutics Suspends Trading Ahead of Debt Facility Update Healthcare Wrap - Week 22 (25 May -> 29 May) 2026 Wrap
22 May 2026 · 09:38 am AEST ⚡ Price Sensitive ASX Filing
Trading Halt
Trading Halt
14 May 2026 · 11:33 am AEST ASX Filing
Phase 1 IRX-616a Last Patient Last Dose
Progress Report
13 May 2026 · 01:10 pm AEST ASX Filing
Director Appointment/Resignation
Initial Director's Interest NoticeFinal Director's Interest Notice

30 Apr 2026 · 05:13 pm AEST ASX Filing
2026 AGM - Sample Proxy Form
Proxy Form
30 Apr 2026 · 05:12 pm AEST ASX Filing
2026 AGM - Access Letter
Notice of Annual General MeetingLetter to Shareholders
30 Apr 2026 · 05:10 pm AEST ASX Filing
Notice of Annual General Meeting
Web CastNotice of Annual General Meeting
30 Apr 2026 · 02:40 pm AEST ⚡ Price SensitiveMaterial ASX Filing
Mar26 Appendix 4C Cash Flow Report
Nexalis Therapeutics reports Q1 2026 cash flow with strong financing support for clinical trials
Commitments Test Entity - First Quarter Cashflow Report
60
30 Apr 2026 · 02:40 pm AEST ⚡ Price SensitiveMaterial ASX Filing
Mar26 Quarterly Activities Report
Nexalis Therapeutics advances clinical trials and rebrands as NX1 with strong pipeline progress and capital raising
Commitments Test Entity - First Quarter Activity Report
75
28 Apr 2026 · 09:25 am AEST Material ASX Filing
Phase 1 IRX-616a Trial Advances to Final Cohort
Nexalis Advances to Final Cohort in Phase 1 Trial of Rapid-Onset Anxiety Treatment IRX-616a
Progress Report
75
23 Apr 2026 · 09:41 am AEST ASX Filing
US Policy Market Advancement Supports SRX-25 TRD Treatment
Progress Report
20 Apr 2026 · 09:59 am AEST ⚡ Price SensitiveMaterial ASX Filing
Significant Milestone - First Patient Screened IRX-211 Ph2
Nexalis screens first patient in Phase 2 trial of IRX-211 for breakthrough cancer pain
Progress Report
80
Nexalis Screens First Patient in Phase 2 Trial Targeting Breakthrough Cancer Pain Healthcare Wrap - Week 17 (20 Apr -> 24 Apr) 2026 Wrap
17 Apr 2026 · 09:50 am AEST Material ASX Filing
Phase 1 IRX-616a Trial Advances - Positive Safety Review
Nexalis completes first cohort dosing in Phase 1 trial of inhaled CBD for panic disorder, moves to second cohort
Progress Report
70